Tokushima University / Educator and Researcher Directory --- Ishikawa, Daichi

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Daichi Ishikawa, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Mitsuo Shimada : Anastomotic recurrence after laparoscopic distal gastrectomy with delta-shaped anastomosis : report of a case., The Journal of Medical Investigation : JMI, Vol.67, No.1.2, 211-213, 2020. (Summary) Delta-shaped anastomosis is nowadays an increasingly performed reconstruction method in laparoscopic distal gastrectomy for early gastric cancer. To date, anastomotic recurrence at the delta-shaped anastomotic site has not been reported. Surgery for this disease is more complicated than anastomotic recurrence at the site of conventional Billroth-I anastomosis. A 68-year-old female was referred to our institute with early gastric cancer on the posterior wall of the antrum. She underwent laparoscopic distal gastrectomy with delta-shaped Billroth-I anastomosis. Follow-up gastrofiberscopy 16 months after the operation revealed suspected anastomotic recurrence, and gastric biopsy revealed signet-ring cell carcinoma. Open total gastrectomy with reconstruction with the Roux-en-Y method was performed. At the distal part of the previous anastomosis, an adequate length of the duodenum was dissected from the pancreas. Then, the duodenum was transected 3 cm distal to the anastomosis using a linear stapler. The patient recovered well and was discharged on postoperative day 14. The patient is alive without re-recurrence 3 years postoperatively. We successfully treated a patient with anastomotic recurrence of gastric cancer after delta-shaped anastomosis. Adequate resection of the duodenal stump was performed without any residual tumor or injury to the pancreas. J. Med. Invest. 67 : 211-213, February, 2020. (Keyword) Aged / Anastomosis, Surgical / Female / Gastrectomy / Humans / Laparoscopy / Neoplasm Recurrence, Local / Recurrence / Stomach Neoplasms (Tokushima University Institutional Repository) ● Metadata: 114831 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.211 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32378612 ● Search Scopus @ Elsevier (PMID): 32378612 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.211 (Tokushima University Institutional Repository: 114831, DOI: 10.2152/jmi.67.211, PubMed: 32378612)
2.	Daichi Ishikawa, Kouzou Yoshikawa, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga, Jun Higashijima and Mitsuo Shimada : Expression Level of MicroRNA-449a Predicts the Prognosis of Patients With Gastric Cancer., Anticancer Research, Vol.40, No.1, 239-244, 2020. (Summary) In previous studies, we demonstrated the significant role of microRNA-449a (miR-449a) in colorectal cancer with in vivo and clinical samples. The importance of miR-449a in gastric cancer is still to be elucidated. This study examined the impact of miR-449a expression in tumor tissue and serum and investigated its potential as a prognostic marker in gastric cancer. Sixty-six patients with gastric cancer who underwent surgery were included in the study. miR-449a expression in tumor tissue and serum were investigated by real-time polymerase chain reaction analysis. The association of miR-449a expression with clinicopathological factors and patient prognosis were also investigated. miR-449a expression was lower in tumor tissue than non-tumor tissue. miR-449a in tumor tissue negatively correlated with the malignancy of tumor and clinical stage. Increased carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels were seen at significantly higher frequencies in patients with low miR-449a expression. Patients with low miR-449a expression had poorer cancer-specific survival compared to those with high miR-449a expression. The univariate analysis showed that lymphovascular invasion, increased CEA and CA19-9 and a low expression of miR-449a were associated with a poorer 5-year cancer-specific survival. miR-449a expression level in serum correlated to that in tumor tissue and was also associated with tumor malignancy. The miR-449a level in tumor tissue might be useful as a prognostic indicator for patients with gastric cancer and miR-449a in serum appears to reflect its expression in tumor tissue. (Keyword) Aged / Disease-Free Survival / Female / Gene Expression Regulation, Neoplastic / Humans / Male / MicroRNAs / Prognosis / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.13945 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31892572 ● Search Scopus @ Elsevier (PMID): 31892572 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.13945 (DOI: 10.21873/anticanres.13945, PubMed: 31892572)
3.	Daichi Ishikawa, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga, Jun Higashijima, Kouzou Yoshikawa, Koji Yasutomo and Mitsuo Shimada : The Significance of MicroRNA-449a and Its Potential Target HDAC1 in Patients With Colorectal Cancer., Anticancer Research, Vol.39, No.6, 2855-2860, 2019. (Summary) miR-449a level might be a prognostic indicator for colorectal cancer and miR-449a might regulate HDAC1 expression. (Keyword) Aged / Antigens, Tumor-Associated, Carbohydrate / Colorectal Neoplasms / Female / Gene Expression Regulation, Neoplastic / Histone Deacetylase 1 / Humans / Liver Neoplasms / Male / MicroRNAs / Middle Aged / Neoplasm Invasiveness / Prognosis / Survival Analysis (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.13414 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31177123 ● Search Scopus @ Elsevier (PMID): 31177123 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.13414 (DOI: 10.21873/anticanres.13414, PubMed: 31177123)
4.	Tumenjin Enkhbat, Masaaki Nishi, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Masahide Tominaga and Mitsuo Shimada : Epigallocatechin-3-gallate Enhances Radiation Sensitivity in Colorectal Cancer Cells Through Nrf2 Activation and Autophagy., Anticancer Research, Vol.38, No.11, 6247-6252, 2018. (Summary) Epigallocatechin-3-gallate (EGCG) is a major polyphenolic component of green tea. EGCG plays a potential role in radio-sensitizing cancer cells. The combined effect of EGCG and radiation was investigated in a colorectal cancer cell line, focusing on nuclear factor (erythroid-derived 2)-like 2 (Nrf2) autophagy signalling. HCT-116 cells were treated with 12.5 μM EGCG for different periods of time, 2 Gy radiation, or both. Cell viability was determined with the WST-8 assay. The number of colonies was determined with the colony formation assay. mRNA expression of LC3 and caspase-9 was analyzed with quantitative real-time polymerase chain reaction. Combination treatment with EGCG and radiation significantly decreased the growth of HCT-116 cells. The number of colonies was reduced to 34.2% compared to the control group. Immunofluorescence microscopy images showed that nuclear translocation of Nrf2 was significantly increased when cells were treated with the combination of EGCG and radiation compared to the control and single-treatment groups. Combined treatment with EGCG and radiation significantly induced LC3 and caspase-9 mRNA expression. EGCG increased the sensitivity of colorectal cancer cells to radiation by inhibiting cell proliferation and inducing Nrf2 nuclear translocation and autophagy. (Keyword) Caspase 9 / Catechin / Cell Nucleus / Cell Proliferation / Cell Survival / Colorectal Neoplasms / Gene Expression Regulation, Neoplastic / HCT116 Cells / Humans / Microtubule-Associated Proteins / NF-E2-Related Factor 2 / Protein Transport / Radiation-Sensitizing Agents / Transcriptional Activation (Tokushima University Institutional Repository) ● Metadata: 113340 (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.12980 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30396944 ● Summary page in Scopus @ Elsevier: 2-s2.0-85056084372 (Tokushima University Institutional Repository: 113340, DOI: 10.21873/anticanres.12980, PubMed: 30396944, Elsevier: Scopus)
5.	Tumenjin Enkhbat, Masaaki Nishi, Chie Takasu, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Daichi Ishikawa and Mitsuo Shimada : Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer., Anticancer Research, Vol.38, No.6, 3367-3373, 2018. (Summary) Programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1(PD-L1) axis is associated with immune tolerance via inhibition of T cell activation. The aim of this study was to clarify the significance of PD-1 and PD-L1 expressions and analyze the relationships between PD-1, PD-L1, transforming growth factor-β (TGF-β) and Forkhead box P3 (Foxp3) expressions in colorectal cancer (CRC). A total of 116 patients who underwent curative colectomy for stage II/III CRC were included in the study. PD-1, PD-L1, TGF-β, and Foxp3 expressions were examined by immunohistochemistry and related to prognostic factors by Kaplan-Meier. PD-1 expression was correlated with PD-L1, TGF-β, and Foxp3 expressions. Overall survival rates were significantly poorer in the PD-1 and PD-L1-positive groups. Multivariate analysis showed that PD-L1-positive is an independent risk factor. Disease-free survival (DFS) was tended in the PD-L1-positive group. The group with double-positive expression had significantly poorer prognosis. PD-1 and PD-L1 expressions were associated with a poor prognosis and correlated with TGF-β and Foxp3 expressions in patients with CRC. (Keyword) Adult / Aged / Aged, 80 and over / B7-H1 Antigen / Colectomy / Colorectal Neoplasms / Female / Forkhead Transcription Factors / Humans / Immunohistochemistry / Kaplan-Meier Estimate / Male / Middle Aged / Prognosis / Programmed Cell Death 1 Receptor / Transforming Growth Factor beta (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.12603 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29848685 ● Summary page in Scopus @ Elsevier: 2-s2.0-85048247787 (DOI: 10.21873/anticanres.12603, PubMed: 29848685, Elsevier: Scopus)
6.	Masaaki Nishi, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Yuma Wada and Mitsuo Shimada : The Impact of Indoleamine 2,3-dioxygenase (IDO) Expression on Stage III Gastric Cancer., Anticancer Research, Vol.38, No.6, 3387-3392, 2018. (Summary) Indoleamine 2,3-dioxygenase (IDO) down-regulates T cell activation, attenuates regulatory T cell (Treg) activation and is related to immune tolerance. The aim of the study was to clarify the significance of IDO expression and analyze the relationships between the expression of IDO, TGF-β, and Foxp3 in gastric cancer (GC). A total of 60 patients who underwent curative gastrectomy for stage III gastric cancer were included in the study. The expression of IDO, TGF-β, and Foxp3 was examined by immunohistochemistry and the relationship of each expression level to several prognostic factors was examined using univariate and multivariate analyses. IDO expression was not positively correlated with any of the factors examined. IDO expression was positively correlated with TGF-β expression (p<0.05), and TGF-β expression was positively correlated with FoxP3 expression (p<0.05). Overall survival (OS) rates were significantly poorer in the IDO-positive group compared to the IDO-negative group (3-year OS, 78.5% vs. 90%, respectively; p<0.05). Multivariate analysis confirmed IDO expression as independent prognostic factors in OS. Disease-free survival (DFS) was significantly poorer in the IDO-positive group compared to the IDO-negative group (3-year DFS, 59.3% vs. 69.3%, respectively; p<0.05). IDO is associated with poor prognosis and immuno-tolerance through attenuation of Treg activation in Stage III GC. (Keyword) Adult / Aged / Aged, 80 and over / Female / Forkhead Transcription Factors / Gastrectomy / Humans / Immunohistochemistry / Indoleamine-Pyrrole 2,3,-Dioxygenase / Kaplan-Meier Estimate / Male / Middle Aged / Multivariate Analysis / Neoplasm Staging / Prognosis / Stomach Neoplasms / T-Lymphocytes, Regulatory / Transforming Growth Factor beta1 (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.12605 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29848687 ● Summary page in Scopus @ Elsevier: 2-s2.0-85048212303 (DOI: 10.21873/anticanres.12605, PubMed: 29848687, Elsevier: Scopus)
7.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara and Daichi Ishikawa : Usefulness of the Transoral Anvil Delivery System for Esophagojejunostomy After Laparoscopic Total Gastrectomy: A Single-institution Comparative Study of Transoral Anvil Delivery System and the Overlap Method., Surgical Laparoscopy, Endoscopy & Percutaneous Techniques, Vol.28, No.2, e40-e43, 2018. (Summary) Many reconstruction techniques have been reported after laparoscopic total gastrectomy (LTG), but it is not clear which anastomosis technique is most useful, and no standard methods have been established. This study examined whether LTG using the transoral anvil delivery system (TOADS) is a feasible and safe procedure for gastric cancer. A series of 47 patients underwent the overlap method and 36 underwent the hemi-double-stapling technique with TOADS. Intraoperative and postoperative outcomes were compared between the 2 groups. In the TOADS group, operation time for reconstruction was shorter (16 3 vs. 45 10in, P=0.003), and blood loss was reduced (45 15 vs. 126 13L, P=0.0002). There were no significant differences in intraoperative complications, conversion to open surgery, and intraoperative anastomosis-related complications between the 2 groups. Furthermore, there were no significant differences in the incidence of complications, reoperation, mortality, and postoperative hospital stay. LTG using TOADS for gastric cancer may be a technically feasible surgical procedure with acceptable morbidity. (Keyword) Adult / Aged / Aged, 80 and over / Esophagostomy / Female / Follow-Up Studies / Gastrectomy / Humans / Jejunostomy / Laparoscopy / Male / Middle Aged / Mouth / Natural Orifice Endoscopic Surgery / Operative Time / Postoperative Complications / Reoperation / Retrospective Studies / Stomach Neoplasms / Suture Techniques / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1097/SLE.0000000000000495 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29064880 ● Search Scopus @ Elsevier (PMID): 29064880 ● Search Scopus @ Elsevier (DOI): 10.1097/SLE.0000000000000495 (DOI: 10.1097/SLE.0000000000000495, PubMed: 29064880)
8.	Satoru Imura, Hiroki Teraoku, Masato Yoshikawa, Daichi Ishikawa, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Potential predictive factors for microvascular invasion in hepatocellular carcinoma classified within the Milan criteria., International Journal of Clinical Oncology, Vol.23, No.1, 98-103, 2018. (Summary) Microvascular invasion (mvi) is an important risk factor for recurrent hepatocellular carcinoma (HCC), even after curative liver resection or orthotopic liver transplantation. However, mvi is difficult to detect preoperatively. The aim of this study was to clarify the risk factors of postoperative recurrence and investigate predictive factors of mvi before hepatectomy for HCC classified within the Milan criteria. One hundred fifty-nine patients with hepatocellular carcinoma (HCC) classified within the Milan criteria, who underwent hepatectomy, were enrolled in this study. We investigated the risk factors of recurrence. In addition, we divided them into two groups: mvi-negative group and mvi-positive group, based on pathological findings after surgery. We compared the clinicopathological factors between the two groups and determined the risk factors for mvi. Overall survival rate at 1, 3, and 5 years were 91.6%, 80.5%, and 74.9%, and the recurrence-free survival rate at 1, 3, and 5-years were 72.3%, 51.6%, and 37.2%. Risk factor analysis for tumor recurrence revealed that total bilirubin, albumin, ICGR15, AFP-L3, tumor number, mvi, and tumor stage had a significant predictive value. Multivariate analysis revealed that tumor number and mvi were significant independent risk factors for tumor recurrence. Predictive analysis for risk factors of mvi revealed that multiple tumors and AFP-L3 > 10% were significant independent risk factors for mvi in HCC classified within the Milan criteria. The mvi was one of the independent risk factors for tumor recurrence in HCC classified within the Milan criteria. Multiple tumors and high AFP-L3 value were independent predictive factors for mvi. (Keyword) Aged / Bilirubin / Carcinoma, Hepatocellular / Disease-Free Survival / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged / Multivariate Analysis / Neoplasm Recurrence, Local / Retrospective Studies / Risk Factors / Survival Rate (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-017-1189-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28875240 ● Summary page in Scopus @ Elsevier: 2-s2.0-85028981662 (DOI: 10.1007/s10147-017-1189-8, PubMed: 28875240, Elsevier: Scopus)
9.	Toshiaki Yoshimoto, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Daichi Ishikawa, Hiroki Teraoku, Yoshimi Bando and Mitsuo Shimada : The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy., Anticancer Research, Vol.38, No.1, 501-507, 2018. (Summary) We report the outcomes of sorafenib therapy for advanced hepatocellular carcinoma (HCC) in our Department. Thirty-eight patients with unresectable HCC who were administrated sorafenib from 2009 to 2015 were investigated retrospectively. The 1-year overall survival rate was 59.3%. The macroscopic vascular invasion and response rate were independent prognostic factors of survival. Surgical resection after sorafenib achieved long-term survival in two cases. Case 1: A patient with locally unresectable HCC showed significant response induced by sorafenib, which allowed complete surgical resection. This tumor tested positive for FGF4. Case 2: A patient with a history of hepatectomy for HCC had multiple distant metastases. Most lesions were reduced in size after sorafenib therapy and new lesions in the remnant liver and residual lung metastases were resected. The sorafenib-resistant lesions were negative for FGF4. Sorafenib combined with surgical resection is a feasible option in advanced HCC patients, if sorafenib has been effective. (Keyword) Adult / Aged / Aged, 80 and over / Antineoplastic Agents / Carcinoma, Hepatocellular / Combined Modality Therapy / Female / Fibroblast Growth Factor 4 / Hepatectomy / Hepatitis B / Humans / Liver Neoplasms / Male / Middle Aged / Niacinamide / Phenylurea Compounds / Retrospective Studies / Salvage Therapy / Sorafenib / Survival Rate (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.12250 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29277815 ● Summary page in Scopus @ Elsevier: 2-s2.0-85039796842 (DOI: 10.21873/anticanres.12250, PubMed: 29277815, Elsevier: Scopus)
10.	Masanori Niki, Kohhei Nakajima, Daichi Ishikawa, Jun Nishida, Chieko Ishifune, Shin-ichi Tsukumo, Mitsuo Shimada, Shinji Nagahiro, Yoshinori Mitamura and Koji Yasutomo : MicroRNA-449a deficiency promotes colon carcinogenesis., Scientific Reports, Vol.7, No.1, 10696, 2017. (Summary) MicroRNAs have broad roles in tumorigenesis and cell differentiation through regulation of target genes. Notch signaling also controls cell differentiation and tumorigenesis. However, the mechanisms through which Notch mediates microRNA expression are still unclear. In this study, we aimed to identify microRNAs regulated by Notch signaling. Our analysis found that microRNA-449a (miR-449a) was indirectly regulated by Notch signaling. Although miR-449a-deficient mice did not show any Notch-dependent defects in immune cell development, treatment of miR-449a-deficient mice with azoxymethane (AOM) or dextran sodium sulfate (DSS) increased the numbers and sizes of colon tumors. These effects were associated with an increase in intestinal epithelial cell proliferation following AOM/DSS treatment. In patients with colon cancer, miR-449a expression was inversely correlated with disease-free survival and histological scores and was positively correlated with the expression of MLH1 for which loss-of function mutations have been shown to be involved in colon cancer. Colon tissues of miR-449a-deficient mice showed reduced Mlh1 expression compared with those of wild-type mice. Thus, these data suggested that miR-449a acted as a key regulator of colon tumorigenesis by controlling the proliferation of intestinal epithelial cells. Additionally, activation of miR-449a may represent an effective therapeutic strategy and prognostic marker in colon cancer. (Tokushima University Institutional Repository) ● Metadata: 112383 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-017-10500-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28878284 ● Summary page in Scopus @ Elsevier: 2-s2.0-85029002400 (Tokushima University Institutional Repository: 112383, DOI: 10.1038/s41598-017-10500-0, PubMed: 28878284, Elsevier: Scopus)

Academic Paper (Unrefereed Paper):

1.	Masaaki Nishi, Mitsuo Shimada, Takuya Tokunaga, Jun Higashijima, Kouzou Yoshikawa, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Yuuma Wada, Shohei Eto and Toshiaki Yoshimoto : Lymphocyte to C-reactive protein ratio predicts long-term outcomes for patients with lower rectal cancer., World Journal of Surgical Oncology, Vol.19, No.1, 201, 2021. (Summary) The lymphocyte to C-reactive protein (CRP) ratio (LCR) is an indicator of systemic inflammation and host-tumor cell interactions. The aim of this study was to investigate the prognostic significance of LCR in lower rectal cancer patients who received preoperative chemo-radiotherapy (CRT). Forty-eight patients with lower rectal cancer who underwent CRT followed by curative surgery were enrolled in this study. Routine blood examinations were performed before and after CRT were used to calculate pre-CRT LCR and post-CRT LCR. The median LCR was used to stratify patients into low and high LCR groups for analysis. The correlation between pre- and post-CRT LCR and clinical outcomes was retrospectively investigated. The pre-CRT LCR was significantly higher than the post-CRT LCR (11,765 and 6780, respectively, P < 0.05). The 5-year overall survival rate was significantly higher for patients with high post-CRT LCR compared with low post-CRT LCR (90.6% and 65.5%, respectively, P < 0.05). In univariate analysis, post-CRT LCR, post-CRT neutrophil to lymphocyte ratio, and fStage were significant prognostic factors for overall survival. In multivariate analysis, post-CRT LCR, but not other clinicopathological factors or prognostic indexes, was a significant prognostic factor for overall survival (P < 0.05). Post-CRT LCR could be a prognostic biomarker for patients with lower rectal cancer. (Keyword) C-Reactive Protein / Chemoradiotherapy / Humans / Lymphocytes / Neoplasm Staging / Prognosis / Rectal Neoplasms / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 117394 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12957-021-02319-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34229704 ● Search Scopus @ Elsevier (PMID): 34229704 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-021-02319-x (Tokushima University Institutional Repository: 117394, DOI: 10.1186/s12957-021-02319-x, PubMed: 34229704)
2.	Shogo Oota, Masaaki Nishi, Takuya Tokunaga, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Mitsuo Shimada : Usefulness of an ICG fluorescence catheter system in TaTME for avoiding intraoperative urethral injury., The Journal of Medical Investigation : JMI, Vol.67, No.3.4, 285-288, 2020. (Summary) Sometimes intraoperative urethral injury occurs in Transanal total mesorectal excision (TaTME). The aim of this study is to investigate the usefulness of indocyanine green (ICG) fluorescent catheter system for avoiding intraoperative urethral injury in TaTME in experimental model. A urethral catheter was filled with the mixture of albumin and ICG and raw hams were applied in layers as the surrogate model of rectourethral muscle. The detectability of ICG fluorescence in this catheter was investigated by using laparoscope-type fluorescence camera system. Fluorescence was detected when ICG was mixed with albumin or peripheral blood. ICG fluorescence could be detected within 4 mm depth of layered raw hams as the surrogate model. Quantitative analysis of the picture detected that ICG fluorescence plateaued in lower concentration than that of serum. ICG fluorescent catheter system may be useful for avoiding intraoperative urethral injury in TaTME. J. Med. Invest. 67 : 285-288, August, 2020. (Tokushima University Institutional Repository) ● Metadata: 115426 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.285 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33148903 ● Search Scopus @ Elsevier (PMID): 33148903 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.285 (Tokushima University Institutional Repository: 115426, DOI: 10.2152/jmi.67.285, PubMed: 33148903)
3.	Yuuma Wada, Masaaki Nishi, Kouzou Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Toshiaki Yoshimoto and Mitsuo Shimada : Usefulness of virtual three-dimensional image analysis in inguinal hernia as an educational tool., Surgical Endoscopy, Vol.34, No.2, 1923-1928, 2020. (Summary) The pre-operative three-dimensional (3D) imaging technique has resulted in a better surgical outcome for patients and has been used as an education and diagnostic tool. However, there are no reports concerning the usefulness of the 3D imaging technique in laparoscopic transabdominal pre-peritoneal repair (TAPP) so the aim of this study was to investigate the usefulness of the 3D imaging technique in laparoscopic TAPP as an educational tool for medical students. Six (6) patients who underwent laparoscopic TAPP for inguinal hernia were enrolled in this study. 3D reconstruction was performed from pre-operative computed tomography (CT) and the usefulness of pre-operative 3D simulation compared with intra-operative laparoscopic imaging was validated. Moreover, thirty (30) medical students at the university completed a multiple-choice questionnaire (MCQ) to determine the level of their satisfaction and understanding of anatomy resulting from the study. The local anatomy of the patients was identified as the same during the operation as the pre-operative 3D simulation. The results of the MCQ showed that most of the medical students were extremely (23%) or very (67%) satisfied with the effect of pre-operative 3D simulation on the quality of the surgery. Moreover, most students could understand the surgery anatomy by the 3D simulation extremely well (40%) or very well (47%) and agreed on the usefulness of this procedure for learning anatomy. Pre-operative 3D simulation increases the understanding of detailed anatomy and virtual three-dimensional image analysis in laparoscopic TAPP is useful as an educational tool for medical students. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-019-06964-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31312962 ● Search Scopus @ Elsevier (PMID): 31312962 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-019-06964-y (DOI: 10.1007/s00464-019-06964-y, PubMed: 31312962)
4.	Daichi Ishikawa, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Takuya Tokunaga, Jun Higashijima, Kouzou Yoshikawa and Mitsuo Shimada : The Role of Neutrophil-to-lymphocyte Ratio on the Effect of CRT for Patients With Rectal Cancer., In Vivo, Vol.34, No.2, 863-868, 2020. (Summary) Neutrophil-to-lymphocyte ratio (NLR) is an indicator of systemic inflammation and could be a predictive factor in malignant tumors. The aim of this study was to investigate the impact of NLR in patients with lower rectal cancer who received preoperative chemo-radiotherapy (CRT). Forty-eight patients with lower rectal cancer who underwent preoperative CRT and curative resection were enrolled. Blood samples were obtained before and after CRT. The relationship of NLR with clinical outcome was investigated. Post-CRT NLR was higher compared to pre-CRT NLR. The patients with higher post-CRT NLR tended to have worse pathological response to CRT compared to those with low post-CRT NLR. The patients with high post-CRT NLR showed poorer 5-year overall survival and 3-year disease free survival while there was no correlation according to pre-CRT NLR. The univariate analysis showed that post-CRT stage and post-CRT NLR were associated with a poorer 5-year overall survival. NLR after preoperative CRT could be a potential prognostic indicator for patients with lower rectal cancer. (Keyword) Aged / Aged, 80 and over / Biomarkers, Tumor / Chemoradiotherapy / Combined Modality Therapy / Female / Humans / Leukocyte Count / Lymphocytes / Male / Middle Aged / Neoplasm Staging / Neutrophils / Preoperative Care / Prognosis / Rectal Neoplasms / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.11850 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32111796 ● Search Scopus @ Elsevier (PMID): 32111796 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.11850 (DOI: 10.21873/invivo.11850, PubMed: 32111796)
5.	Masaaki Nishi, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa and Mitsuo Shimada : Utility of virtual three-dimensional image analysis for laparoscopic gastrectomy conducted by trainee surgeons., The Journal of Medical Investigation : JMI, Vol.66, No.3.4, 280-284, 2019. (Summary) Purpose The aim of this study was to investigate the utility the three-dimensional (3D) imaging for laparoscopic gastrectomy performed by trainee surgeons. Methods 3D-reconstruction was performed using multi-detector computed tomography (MDCT) and SYNAPSE VINCENT software. Trainee surgeons made 3D-imaging and checked the anatomical structure. Thirty-three patients who underwent laparoscopic gastrectomy (LG) for gastric cancer were examined. Trainees performed 19 LG, while specialists performed 14 LG. The vascular pattern and the surgical outcomes were evaluated. Result 3D imaging depicted the correct positional relationship between the gastric vasculatures and the organs. Regarding vascular pattern detected by 3D imaging, the origins of the infrapyloric artery were the right gastroepiploic artery in 12 cases (36%), the gastroduodenal artery in eight cases (24%), the bifurcation of the right gastroepiploic artery and gastroduodenal artery in seven cases (21%), and not detected in one case (3%). The types of confluence of the infrapyloric vein were the right gastroepiploic vein in 16 cases (48%), the anterior superior pancreatoduodenal vein in 10 cases (30%), and not detected in seven cases (21%). Surgical outcomes were not different between trainee group using intraoperative 3D image with the specialist in instruction group without the intraoperative 3D image. Conclusions Preoperative 3D imaging might contribute to successful and safe LG by trainee surgeons. J. Med. Invest. 66 : 280-284, August, 2019. (Tokushima University Institutional Repository) ● Metadata: 114074 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.280 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31656289 ● Search Scopus @ Elsevier (PMID): 31656289 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.66.280 (Tokushima University Institutional Repository: 114074, DOI: 10.2152/jmi.66.280, PubMed: 31656289)
6.	Masaaki Nishi, Bat-Erdene Batsaikhan, Kozo Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa and Mitsuo Shimada : High STAT4 Expression Indicates Better Disease-free Survival in Patients with Gastric Cancer., Anticancer Research, Vol.37, No.12, 6723-6729, 2017. (Summary) The aim of this study was to investigate the significance of signal transducer and activator of transcription 4 (STAT4) expression and the correlation between STAT4 and interferon gamma (IFN- ) in patients with gastric cancer. Sixty-two patients who underwent gastrectomy for gastric cancer were enrolled in the study. STAT4 and IFNG mRNA expression was evaluated by quantitative real-time polymerase chain reaction (PCR). Immunohistochemistry was performed to examine CD8 T-cells, and STAT4 and IFN- expression. STAT4 mRNA expression was significantly correlated with IFNG mRNA expression (p<0.05). Regarding disease-free survival, there was a significant difference between the groups with high and low STAT4 expression (5-year disease-free survival: 77.8% and 56.4%, p<0.05). Univariate analysis revealed that tumor differentiation and STAT4 expression were significant factors for tumor recurrence. High expression of STAT4 in gastric cancer predicted a better clinical outcome. STAT4 might be a useful biomarker to identify patients at high risk of recurrence after gastrectomy. (Keyword) Aged / Disease-Free Survival / Female / Gastrectomy / Gene Expression Regulation, Neoplastic / Humans / Interferon-gamma / Kaplan-Meier Estimate / Male / Neoplasm Recurrence, Local / Outcome Assessment (Health Care) / Prognosis / STAT4 Transcription Factor / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.12131 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29187449 ● Search Scopus @ Elsevier (PMID): 29187449 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.12131 (DOI: 10.21873/anticanres.12131, PubMed: 29187449)
7.	Toshiaki Yoshimoto, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa, Jun Higashijima, Chie Takasu and Mitsuo Shimada : Maximum Diameter and Number of Tumors as a New Prognostic Indicator of Colorectal Liver Metastases., In Vivo, Vol.31, No.3, 419-423, 2017. (Summary) Surgical resection is currently considered the only potentially curative option as a treatment strategy of colorectal liver metastases (CRLM). However, the criteria for selection of resectable CRLM are not clear. The aim of this study was to confirm a new prognostic indicator of CRLM after hepatic resection. One hundred thirty nine patients who underwent initial surgical resection from 1994 to 2015 were investigated retrospectively. Prognostic factors of overall survival including the product of maximum diameter and number of metastases (MDN) were analyzed. Primary tumor differentiation, vessel invasion, lymph node (LN) metastasis, non-optimally resectable metastases, H score, grade of liver metastases, resection with non-curative intent and MDN were found to be prognostic factors of overall survival (OS). In multivariate analyses of clinicopathological features associated with OS, MDN and non-curative intent were independent prognostic factors. Patients with MDN ·30 had shown significantly poorer prognosis than patients with MDN <30 in OS and relapse-free survival (RFS). MDN ·30 is an independent prognostic factor of survival in patients with CRLM and optimal surgical criterion of hepatectomy for CRLM. (Keyword) Adult / Aged / Aged, 80 and over / Cell Differentiation / Colorectal Neoplasms / Female / Follow-Up Studies / Hepatectomy / Humans / Liver Neoplasms / Lymphatic Metastasis / Male / Middle Aged / Multivariate Analysis / Prognosis / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.11076 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28438872 ● Search Scopus @ Elsevier (PMID): 28438872 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.11076 (DOI: 10.21873/invivo.11076, PubMed: 28438872)
8.	Masato Yoshikawa, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Jun Higashijima, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : Elevated Preoperative Serum CEA Level Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma Through the Epithelial-Mesenchymal Transition., Anticancer Research, Vol.37, No.3, 1169-1175, 2017. (Summary) Serum carcinoembryonic antigen (CEA) is used as an indicator of tumor progression in a variety of carcinomas. A subset of patients with hepatocellular carcinoma (HCC) exhibit increased serum CEA level, but the significance of this is unclear. In this study, we investigated the prognosis of patients with HCC with increased serum CEA, and explored the correlations with expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and epithelial-mesenchymal transition (EMT) and tumor angiogenesis. One hundred and twenty-three patients with HCC who underwent radical resection were divided into two groups according to a cut-off value of 5.0 ng/ml for serum CEA: high (n=24) and normal (n=99) groups. We compared the clinicopathological factors with serum CEA levels and its correlations with CEACAM1 expression, EMT-related factors and microvessel density (MVD) of tumor tissues by immunohistochemistry. In the high CEA group, the disease-free survival (DFS) rate was significantly worse than in the normal CEA group. Multivariate analysis revealed that a high CEA level was an independent factor predictive of recurrence. Furthermore, increased serum CEA levels were positively correlated with CEACAM1 expression. Moreover, CEACAM1 expression was positively correlated with expression of EMT-related factors and MVD of tumor tissues. Increased serum CEA level reflected CEACAM1 expression and was an independent factor predictive of recurrence in HCC through EMT and tumor angiogenesis. (Keyword) Adult / Aged / Aged, 80 and over / Antigens, CD / Antigens, CD34 / Cadherins / Carcinoembryonic Antigen / Carcinoma, Hepatocellular / Cell Adhesion Molecules / Disease-Free Survival / Epithelial-Mesenchymal Transition / Female / Follow-Up Studies / Humans / Immunohistochemistry / Liver Neoplasms / Male / Microcirculation / Middle Aged / Neovascularization, Pathologic / Predictive Value of Tests / Preoperative Period / Prognosis / Recurrence / Vimentin (Tokushima University Institutional Repository) ● Metadata: 112034 (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.11430 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28314278 ● Search Scopus @ Elsevier (PMID): 28314278 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.11430 (Tokushima University Institutional Repository: 112034, DOI: 10.21873/anticanres.11430, PubMed: 28314278)

Review, Commentary:

1.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Yuji Morine, Jun Higashijima, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 【がん治療医のための漢方ハンドブック】漢方と癌診療, 臨床外科, Vol.72, No.8, 917-921, Aug. 2017.

Proceeding of International Conference:

1.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : Usefulness of indocyanine green (ICG) fluorescence system and thermography for evaluating bloodflow of intestine in laparoscopic anterior resection., SAGES, Seattle, Apr. 2018.
2.	Takashi Iwata, Masashi Akaike, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Mitsuo Shimada : Usefulness of the rubric evaluation as the qualitative evaluation of the laparoscopic training., SAGES, Seattle, Apr. 2018.
3.	Shogo Oota, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : Transabdominal preperitoneal (TAPP) inguinal hernia repair with liquid-injection and gauze dissection., SAGES, Apr. 2018.
4.	Takuya Tokunaga, Mitsuo Shimada, Masaaki Nishi, Kouzou Yoshikawa, Jun Higashijima, Chie Takasu, Hideya Kashihara and Daichi Ishikawa : The Impact of Indoleamine Two to Three-Dioxygenase (IDO) Expression in Colorectal Cancer., SSO's 71st Annual Cancer Symposium, Chicago, Mar. 2018.
5.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : The impact of indoleamine 2,3-dioxygenase(IDO)expression on stage III gastric cancer., ASCO-GI, San Francisco, Jan. 2018.
6.	Daichi Ishikawa, Jun Higashijima, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga, Kouzou Yoshikawa and Mitsuo Shimada : Preoperative chemoradiotherapy for advanced lower rectal cancer using SOX+Bev regimen and role of microRNA-223 as a predictive indicator for the responder., 第9回日本・モンゴル国際消化器癌シンポジウム, ウランバートル, Aug. 2017.
7.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : The usefulness of the OrVil method and liver mobilization for optimal surgical field in LTG., 第9回日本・モンゴル国際消化器癌シンポジウム, ウランバートル, Aug. 2017.
8.	Masaaki Nishi, Mitsuo Shimada, Tetsuya Ikemoto, Jun Higashijima, Kouzou Yoshikawa, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : Prognostic impact of neutrophil-to-lymphocyte ratio in patients with rectal cancer after preoperative chemoradiotherapy, 47th World Congress of Surgery(WCS), バーゼル, Aug. 2017.
9.	Takashi Iwata, Masashi Akaike, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Daichi Ishikawa and Mitsuo Shimada : Development of the simulator for laparoscopic eye hand coordination training for teaching oneself training, American Gastrointestinal Endoscopic Surgeons, Apr. 2017.
10.	Satoru Imura, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Comparative analysis of the outcome between open and laparoscopic partial liver resection for hepatocellular carcinoma., SAGES, Houston, Mar. 2017.
11.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Toshiaki Yoshimoto and Atsushi Takata : Feasibility of laparoscopic gastrectomy for elderly patients., SAGES, Houston, Mar. 2017.
12.	Takashi Iwata, Masashi Akaike, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Daichi Ishikawa and Mitsuo Shimada : Development of the simulator for laparoscopic eye hand coordination training for teaching oneself training., SAGES, Houston, Mar. 2017.
13.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa and Jun Higashijima : Treatment strategy for colorectal liver metastases:Clinical impact of FOLFOXIRI regimen for unresectable cases., ASCO-GI, San Francisco, Jan. 2017. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2017.35.4_suppl.780 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2017.35.4_suppl.780 (DOI: 10.1200/JCO.2017.35.4_suppl.780)
14.	Daichi Ishikawa, Tetsuya Ikemoto, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Chie Takasu, Yu Saitou, Shuichi Iwahashi, Yuji Morine, Satoru Imura and Mitsuo Shimada : Signigficance of CD4+CD49b+regulatory T cells and Foxp3+regulatory T cells in the peripheral blood of cancer patients, 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
15.	Atsushi Takata, Jun Higashijima, Toshiaki Yoshimoto, Masato Yoshikawa, Daichi Ishikawa, Hideya Kashihara, Masaaki Nishi, Kouzou Yoshikawa and Mitsuo Shimada : The influence of circular muscle incision on intestinal peristalsis and anastomosis, 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
16.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : The usefulness of the OrVil method and liver mobilization for optimal surgical field in laparoscopic total gastrectomy(LTG), 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
17.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : Elevated preoperative serum CEA levels in patients with HCC is associated with prognosis and EMT, 26th World Congress Of the IASGO 2016, Seoul, Sep. 2016.
18.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : The Usefulness of the OrVil Method and Liver Mobilization for Optimal Surgical Field in LATG, 26th World Congress Of the IASGO 2016, Seoul, Sep. 2016.
19.	Satoru Imura, Masato Yoshikawa, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Our strategy for antibody mediated rejection in living donor liver transplantation, 第8回日本・モンゴル消化器癌国際シンポジウム, ウランバートル, Aug. 2016.
20.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Kouzou Yoshikawa and Toshiaki Yoshimoto : The correlation between serum CA19-9 level and the epigenetic alteration in intrahepatic cholangiocarcinoma., IASGO Advanced Post-Graduate Course in Sendai 2016, Sendai, Apr. 2016.
21.	Teraoku Hiroki, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Daichi Ishikawa and Yoshikawa Masato : The expression of Ki-67 is a useful prognostic factor in patients with colorectal liver metastasis, IASGO 2015 post graduate course, Tokyo, Jun. 2015.

Proceeding of Domestic Conference:

1.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : CKLF like MARVEL transmembrane domain containing 6(CMTM6)を介した胃癌再発機構, JDDW2018, Nov. 2018.
2.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : 腹腔鏡下胃切除術における術前減量プログラムの効果, JDDW2018, Nov. 2018.
3.	Takuya Tokunaga, Mitsuo Shimada, Jun Higashijima, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Tomohiko Miyatani : 直腸縫合不全回避のためのICG蛍光法・サーモグラフィーを用いた血流評価の有用性, JDDW2018, Nov. 2018.
4.	Masaaki Nishi, Mitsuo Shimada, Chie Takasu, Hideya Kashihara, Kouzou Yoshikawa, Jun Higashijima, Daichi Ishikawa, Takuya Tokunaga, Yuuma Wada and Tomohiko Miyatani : 胃癌におけるCMTM6発現の意義, 第56回日本癌治療学会学術集会, Oct. 2018.
5.	Shogo Oota, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : NLRを用いた胃癌における再建術式別栄養・免疫機能評価, 第73回日本消化器外科学会総会, Jul. 2018.
6.	Daichi Ishikawa, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga, Jun Higashijima, Kouzou Yoshikawa and Mitsuo Shimada : 再発及び前立腺摘出術後の鼠径ヘルニア症例に対するTAPP法の有用性, 第73回日本消化器外科学会総会, Jul. 2018.
7.	Chie Takasu, Takashi Iwata, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Daichi Ishikawa and Mitsuo Shimada : 大健中湯は小腸パイエル版のPD-1発現を介してバクテリアルトランスロケーション発症を予防する可能性がある, 第73回日本消化器外科学会総会, Jul. 2018.
8.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : Metabolic surgeryのNASH改善メカニズムに関する研究, 第73回日本消化器外科学会総会, Jul. 2018.
9.	Masaaki Nishi, Mitsuo Shimada, Chie Takasu, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Daichi Ishikawa and Yuuma Wada : CMTM6による胃癌再発機構の解明, 第73回日本消化器外科学会総会, Jul. 2018.
10.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Yuuma Wada and Shogo Oota : TaTMEにおける尿道損傷回避のための工夫, 第73回日本消化器外科学会総会, Jul. 2018.
11.	Jun Higashijima, Mitsuo Shimada, Daichi Ishikawa, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Takuya Tokunaga, Kouzou Yoshikawa and Hideya Kashihara : 局所進行下部直腸癌に対する術前化学放射線療法を用いた新たな治療戦略 ~Watch and wait導入へ向けて~, 第73回日本消化器外科学会総会, Jul. 2018.
12.	Takashi Iwata, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : ルーブリック評価を用いた腹腔鏡トレーニングの質的評価と局所解剖理解のためのVR実習の検討, 第73回日本消化器外科学会総会, Jul. 2018.
13.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : 肥満患者に対する腹腔鏡下胃切除術における術前減量プログラムの効果, 第43回日本外科系連合学会学術集会, Jun. 2018.
14.	Takuya Tokunaga, Mitsuo Shimada, Jun Higashijima, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : TaTMEにおける尿道損傷回避のための工夫, 第43回日本外科系連合学会学術集会, Jun. 2018.
15.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : 大腸癌におけるmicroRNA-449a発現の意義, 第27回日本癌病態治療研究会, May 2018.
16.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Daichi Ishikawa and Yuuma Wada : 肥満手術のインスリン抵抗性・NASH改善効果におけるマイクロバイオームの重要性, 第104回日本消化器病学会総会, Apr. 2018.
17.	Daichi Ishikawa, Chie Takasu, Hideya Kashihara, Takuya Tokunaga, Jun Higashijima, Kouzou Yoshikawa, Chie Takasu and Mitsuo Shimada : 胃癌組織中に発現するmicroRNA-449aの意義解明についての研究, 第118回日本外科学会定期学術集会, Apr. 2018.
18.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : 肥満患者に対する腹腔鏡下胃・大腸切除術における術前減量プログラムの効果, 第118回日本外科学会定期学術集会, Apr. 2018.
19.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 腹腔鏡下胃全摘出術の食道空腸吻合法におけるOrVil法の有用性, 第118回日本外科学会定期学術集会, Apr. 2018.
20.	Takashi Iwata, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Masashi Akaike : 腹腔鏡トレーニングの質的評価としてのルーブリック評価の有用性の検討, 第118回日本外科学会定期学術集会, Apr. 2018.
21.	Chie Takasu, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara and Daichi Ishikawa : 大腸癌におけるPD-1/PDL-1発現の意義, 第118回日本外科学会定期学術集会, Apr. 2018.
22.	Shoko Iwahashi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Hirokazu Miki and Masahiro Oura : MDS・発作性夜間血色素尿症を合併する胃癌に対する手術が安全に施行可能であった1例, 第118回日本外科学会定期学術集会, Apr. 2018.
23.	Shogo Oota, Mitsuo Shimada, Masaaki Nishi, Takuya Tokunaga, Jun Higashijima, Daichi Ishikawa, Kouzou Yoshikawa, Chie Takasu, Hideya Kashihara and Yuji Morine : ICG蛍光システムを用いたTaTMEにおける尿道損傷回避に向けた取り組み, 第118回日本外科学会定期学術集会, Apr. 2018.
24.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa and Yuuma Wada : 腫瘍免疫からみた大腸癌再発機構の解明, 第118回日本外科学会定期学術集会, Apr. 2018.
25.	Takuya Tokunaga, Mitsuo Shimada, Jun Higashijima, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Yuuma Wada and Shogo Oota : 腹腔鏡下前方切除術におけるICG蛍光法・サーモグラフィーによる血流評価の有用性, 第118回日本外科学会定期学術集会, Apr. 2018.
26.	Jun Higashijima, Mitsuo Shimada, Shogo Oota, Daichi Ishikawa, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Takuya Tokunaga and Kouzou Yoshikawa : 局所進行直腸癌に対する分子標的薬を加えた術前化学放射線療法の効果と感受性予測:基礎的検討と臨床成績, 第118回日本外科学会定期学術集会, Apr. 2018.
27.	Daichi Ishikawa, Chie Takasu, Hideya Kashihara, Takuya Tokunaga, Masaaki Nishi, Jun Higashijima, Kouzou Yoshikawa and Mitsuo Shimada : 大腸癌の発癌・癌進展におけるmicroRNA-449aの役割解明, 第51回制癌剤適応研究会, Mar. 2018.
28.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Hiroshi Okitsu, 江藤祥平, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : StageIV胃癌に対するConversion surgeryにおける問題点と治療戦略, 第51回制癌剤適応研究会, Mar. 2018.
29.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : 肥満患者に対する腹腔鏡下胃切除術における術前減量プログラム, 第90回日本胃癌学会総会, Mar. 2018.
30.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Hideya Kashihara, Jun Higashijima, Takuya Tokunaga, Chie Takasu and Daichi Ishikawa : LECS for GIST -single center experience-, 第90回日本胃癌学会総会, Mar. 2018.
31.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : The usefulness of the OrVil method and liver mobilization for optimal surgical field in LATG., 第90回日本胃癌学会総会, Mar. 2018.
32.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 鼠径ヘルニア再発症例に対するTAPP法の有用性, 第32回四国内視鏡研究会, Feb. 2018.
33.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Yuma Wada and Shogo Ohta : 当科におけるTaTMEの導入について, 第32回四国内視鏡研究会, Feb. 2018.
34.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 肥満に対する腹腔鏡下Sleeve状胃切除の経験, 第32回四国内視鏡研究会, Feb. 2018.
35.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : ガーゼ剥離を用いた膨潤TAPP―再発症例より学至適剥離・メッシュ展開―, 第30回日本内視鏡外科学会総会, Dec. 2017.
36.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 腹腔鏡下腹壁瘢痕ヘルニア根治術に対するHybrid法の有用性, 第30回日本内視鏡外科学会総会, Dec. 2017.
37.	Takuya Tokunaga, Chie Takasu, Daichi Ishikawa, Hideya Kashihara, Masaaki Nishi, Jun Higashijima, Kouzou Yoshikawa and Mitsuo Shimada : Hybrid法を用いた腹腔鏡下腹壁瘢痕ヘルニア根治術の安全性と有用性, 第79回日本臨床外科学会総会, Nov. 2017.
38.	Daichi Ishikawa, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Jun Higashijima, Kouzou Yoshikawa and Mitsuo Shimada : 鼠径ヘルニア再発症例に対するTAPP法の有用性, 第79回日本臨床外科学会総会, Nov. 2017.
39.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : ガーゼ剥離を用いた膨潤TAPP, 第79回日本臨床外科学会総会, Nov. 2017.
40.	Takashi Iwata, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 腹腔鏡実習におけるルーブリック評価を用いた質的評価の検討, 第79回日本臨床外科学会総会, Nov. 2017.
41.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 下部直腸癌に対するCRT効果予測因子としてのmiR223の意義, 第28回日本消化器癌発生学会総会, Nov. 2017.
42.	Masaaki Nishi, Mitsuo Shimada, Daichi Ishikawa, Chie Takasu, Takuya Tokunaga, Hideya Kashihara, Jun Higashijima and Kouzou Yoshikawa : IDOによる免疫能と胃癌転移機構の解明, 第28回日本消化器癌発生学会総会, Nov. 2017.
43.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Takuya Tokunaga : 胃GISTに対する腹腔鏡・内視鏡合同手術(LECS)の検討, 第108回日本消化器病学会四国支部例会, Nov. 2017.
44.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : The impact of Indoleaine 2,3-dioxygenase (IDO) expression in stagelll gastric cancer, 第55回日本癌治療学会学術集会, Oct. 2017.
45.	Yuuma Wada, Yuji Morine, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Shuichi Iwahashi, Hideya Kashihara, Chie Takasu, Yu Saitou, Daichi Ishikawa, Hiroki Teraoku, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 青色LED光は光受容体(opsin3)を介し癌細胞増殖を抑制する, 第55回日本癌治療学会学術集会, Oct. 2017.
46.	Daichi Ishikawa, Toshiaki Yoshimoto, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 青色LED光は光受容体(opsin)を介し癌細胞増殖を抑制する, 第76回日本癌学会学術総会, Sep. 2017.
47.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : IL driven IL-10 Tr1細胞による細胞レベルのRO/R1手術達成評価に関する検討, 第76回日本癌学会学術総会, Sep. 2017.
48.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 地方におけるロボット手術の現状について, 第92回中国四国外科学会総会, Sep. 2017.
49.	Shoko Iwahashi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto and Shogo Oota : 術前診断が困難であった胃粘膜下異所性胃腺の1例, 第255回徳島医学会学術集会, Aug. 2017.
50.	Chie Takasu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, 市井啓仁 and Mitsuo Shimada : 転写因子制御による肝虚血再灌流障害の新たな治療法の開発, 第255回徳島医学会学術集会, Aug. 2017.
51.	Takashi Iwata, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Masami Nagamune and Masashi Akaike : 腹腔鏡下ペグタッチトレーニングの自学実習を目指したシミュレータの開発, 第49回日本医学教育学会大会, Aug. 2017.
52.	Daichi Ishikawa, Toshiaki Yoshimoto, Chie Takasu, Hideya Kashihara, Jun Higashijima, Kouzou Yoshikawa and Mitsuo Shimada : 大腸癌の発癌・癌進展におけるmicroRNA-449aの役割解明, 第72回日本消化器外科学会総会, Jul. 2017.
53.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Toshiaki Yoshimoto and Atsushi Takata : 下部直腸癌のCRT後NLRは予後不良因子になる, 第72回日本消化器外科学会総会, Jul. 2017.
54.	Jun Higashijima, Daichi Ishikawa, Hideya Kashihara, Chie Takasu, Masaaki Nishi, Kouzou Yoshikawa and Mitsuo Shimada : 局所進行下部直腸癌に対する術前化学放射線療法の長期成績と新たな治療戦略, 第72回日本消化器外科学会総会, Jul. 2017.
55.	Toshiaki Yoshimoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Jun Higashijima : 大腸癌肝転移に切除基準と腫瘍悪性度評価, 第72回日本消化器外科学会総会, Jul. 2017.
56.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 下部直腸癌に対するCRT効果予測因子としてのmiR223の意義, 第87回大腸癌研究会, Jul. 2017.
57.	Daichi Ishikawa, Toshiaki Yoshimoto, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 青色LED光の光受容体(opsin)を介した癌細胞増殖抑制効果の検討, 第42回日本外科系連合学会学術集会, Jun. 2017.
58.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu and Daichi Ishikawa : 外科診療における外来インフォームドコンセント導入の試み, 第42回日本外科系連合学会学術集会, Jun. 2017.
59.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 腹腔鏡下胃癌手術における吻合法の工夫, 第42回日本外科系連合学会学術集会, Jun. 2017.
60.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : ICG蛍光システムを用いた腹腔鏡下前方切除術における縫合不全回避のための新たな戦略, 第42回日本外科系連合学会学術集会, Jun. 2017.
61.	Daichi Ishikawa, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 大腸癌の発癌・腫瘍進展におけるmicroRNA-449aの意義, 第107回日本消化器病学会四国支部例会, Jun. 2017.
62.	Satoru Imura, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Intermediate stageの肝癌に対する切除の有効性の検討, 第53回日本肝臓学会総会, Jun. 2017.
63.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Masato Yoshikawa, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : Tr1 cells and Foxp3+regulatory T cell as a diagnostic biomarker for reflecting pathological agressiveness of cystic neoplasm of pancreas, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
64.	Satoru Imura, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Liver resection for hepatocellular carcinoma of BCLC intermediate stage, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
65.	Daichi Ishikawa, Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 局所進行下部直腸癌に対するSOX+Bevレジメンによる術前化学放射線療法と効果予測因子としてのmiR-223の役割, 第26回日本癌病態治療研究会, Jun. 2017.
66.	Hideya Kashihara, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Takuya Tokunaga, Chie Takasu and Daichi Ishikawa : ガーゼ剥離を用いた膨潤TAPPの有用性, 第71回手術手技研究会, May 2017.
67.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara and Daichi Ishikawa : 腹腔鏡下胃癌手術における吻合術・視野展開の工夫, 第71回手術手技研究会, May 2017.
68.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 胃切除術における肥満の影響と治療成績改善への取り組み, 第117回日本外科学会定期学術集会, Apr. 2017.
69.	Jun Higashijima, Mitsuo Shimada, Kouzou Yoshikawa, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 局所進行下部直腸癌に対するSOX+Bev regimenによる多剤併用術前化学放射線療法, 第117回日本外科学会定期学術集会, Apr. 2017.
70.	Takashi Iwata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Masashi Akaike : 腹腔鏡下eye hand coordinationトレーニングの自学実習を目指したシミュレータの開発, 第117回日本外科学会定期学術集会, Apr. 2017.
71.	Shogo Oota, Yuji Morine, Masato Yoshikawa, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto, Chie Takasu, Jun Higashijima and Mitsuo Shimada : 膵癌術後残膵再発に対する再切除導入効果の検証, 第117回日本外科学会定期学術集会, Apr. 2017.
72.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Yuji Morine, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Atsushi Takata, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 青色LED光は光受容体(opsin)を介し癌細胞増殖を抑制する, 第117回日本外科学会定期学術集会, Apr. 2017.
73.	Atsushi Takata, Jun Higashijima, Daichi Ishikawa, Masato Yoshikawa, Hideya Kashihara, Yu Saitou, Shuichi Iwahashi, Masaaki Nishi, Kouzou Yoshikawa and Mitsuo Shimada : 腸管吻合におけるKono-S吻合の有用性に関する検討, 第117回日本外科学会定期学術集会, Apr. 2017.
74.	Masato Yoshikawa, Rui Feng, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto, Chie Takasu, Jun Higashijima and Mitsuo Shimada : 肝細胞に対するROS/ ERK pathwayを介した赤色LED光の細胞増殖促進効果, 第117回日本外科学会定期学術集会, Apr. 2017.
75.	Daichi Ishikawa, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Chie Takasu, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 大腸癌の発癌・腫瘍進展におけるmicroRNA-449aの意義, 第117回日本外科学会定期学術集会, Apr. 2017.
76.	川下陽一郎, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Daichi Ishikawa, Masato Yoshikawa, Atsushi Takata, Toshiaki Yoshimoto, Hiroki Teraoku and Mitsuo Shimada : 肝内胆管癌におけるHSF1発現の意義, 第117回日本外科学会定期学術集会, Apr. 2017.
77.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Yuji Morine, Satoru Imura, Jun Higashijima, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Masato Yoshikawa and Toshiaki Yoshimoto : Tr1細胞とFoxp3調節性T細胞による腫瘍免疫状態を反映する免疫学的バイオマーカー探索, 第117回日本外科学会定期学術集会, Apr. 2017.
78.	Satoru Imura, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Jun Higashijima, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 肝切除シミュレーション・ナビゲーションを駆使した若手教育法の確立, 第117回日本外科学会定期学術集会, Apr. 2017.
79.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Jun Higashijima and Chie Takasu : 大腸癌肝転移における治療指針 - 原発・転移巣の腫瘍悪性度は相関しない?, 第117回日本外科学会定期学術集会, Apr. 2017.
80.	Yuji Morine, Hiroki Ishibashi, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Mitsuo Shimada : 「胆道拡張症，膵・胆管合流異常症の標準術式は?-小児外科および成人外科の立場から-」, 第117回日本外科学会定期学術集会, Apr. 2017.
81.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Hideya Kashihara, Jun Higashijima, Takuya Tokunaga, Chie Takasu and Daichi Ishikawa : 超高齢者に対する腹腔鏡下胃切除は安全に施行可能か?, 第103回日本消化器病学会総会, Apr. 2017.
82.	Daichi Ishikawa, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 腹腔鏡下前方切除術におけるICG蛍光システムを利用した予防的回腸ストーマ造設の適応, 第31回中国四国ストーマリハビリテーション研究会, Mar. 2017.
83.	Jun Higashijima, Daichi Ishikawa, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Kouzou Yoshikawa and Mitsuo Shimada : 肛門温存を可能とする早期下部直腸癌に対する術前化学放射線療法併用局所切除術の成績について, 第31回中国四国ストーマリハビリテーション研究会, Mar. 2017.
84.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Hideya Kashihara, Takuya Tokunaga, Chie Takasu, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : Indoleamine 2,3-dioxygenase(IDO)による胃癌再発機構, 第50回制癌剤適応研究会, Mar. 2017.
85.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Masato Yoshikawa : 肥満の胃切除術への影響と肥満患者における治療成績改善への取り組み, 第89回日本胃癌学会総会, Mar. 2017.
86.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Chie Takasu, Jun Higashijima, Takuya Tokunaga, Hideya Kashihara and Daichi Ishikawa : IDOによる胃癌再発機構の解明, 第89回日本胃癌学会総会, Mar. 2017.
87.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Chie Takasu, Hideya Kashihara, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : 術前診断が困難であった胃粘膜下異所性胃腺の1例, 第66回日本消化器画像診断研究会, Feb. 2017.
88.	Masaaki Nishi, Jun Higashijima, Daichi Ishikawa, Hideya Kashihara, Chie Takasu, Takuya Tokunaga and Kouzou Yoshikawa : 下部直腸癌に対するCRT効果予測因子としてのmiR-223の意義, 第13回日本消化管学会総会学術集会, Feb. 2017.
89.	Daichi Ishikawa, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara and Chie Takasu : 腹腔鏡下前方切除術における縫合不全回避のためのICG蛍光システムの有用性, 第25回徳島外科術後管理研究会, Feb. 2017.
90.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Masato Yoshikawa : 胃切除術における肥満の影響と治療成績改善への取り組み, 第25回徳島外科術後管理研究会, Feb. 2017.
91.	Toshiaki Yoshimoto, Masato Yoshikawa, Daichi Ishikawa, Atsushi Takata, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : Long-term survivors of HCC using sorafenib, 2nd Eastern &Western Association Liver Tumors(EWALT), Jan. 2017.
92.	Masato Yoshikawa, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : 肝細胞癌術後再発予後不良因子としてのCEAの意義, 第15回日本肝がん分子標的治療研究会, Jan. 2017.
93.	Masato Yoshikawa, Rui Feng, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, Masaaki Nishi, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : 肝細胞に対するROS/ERK pathwayを介した赤色LED光の細胞増殖促進効果, 第46回日本創傷治癒学会, Dec. 2016.
94.	Satoru Imura, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 定型化と教育システムがもたらす安全な腹腔鏡下左葉切除, 第29回日本内視鏡外科学会総会, Dec. 2016.
95.	Jun Higashijima, Daichi Ishikawa, Hideya Kashihara, Masaaki Nishi, Kouzou Yoshikawa and Mitsuo Shimada : 腹腔鏡下前方切除術における縫合不全回避のための戦略, 第29回日本内視鏡外科学会総会, Dec. 2016.
96.	Masato Yoshikawa, Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Daichi Ishikawa, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : 若手医師による術前術中3D simulation画像を用いた腹腔鏡下手術の定型化, 第25回日本コンピュータ外科学会大会, Nov. 2016.
97.	Masato Yoshikawa, Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : 再発膵癌に対する再切除の有用性の検討, 第78回日本臨床外科学会総会, Nov. 2016.
98.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 当科における若手医師の腹腔鏡手術トレーニングの現状と効果, 第78回日本臨床外科学会総会, Nov. 2016.
99.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 若手外科医でも安全・確実に施行できる肝葉切除術, 第78回日本臨床外科学会総会, Nov. 2016.
100.	Yu Saitou, Yuji Morine, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Daichi Ishikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 膵頭十二指腸切除術に対するModified de-rotation法を用いた`` Complete artery-f irst approach'', 第78回日本臨床外科学会総会, Nov. 2016.
101.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 膵全摘における人工膵臓の有用性における検討, 第78回日本臨床外科学会総会, Nov. 2016.
102.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa, Chie Takasu, Yusuke Arakawa and Jun Higashijima : 大腸癌切除不能多発肝転移に対する治療戦略, 第78回日本臨床外科学会総会, Nov. 2016.
103.	Satoru Imura, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : グリソン一括による肝門処理のコツとピットフォール, 第78回日本臨床外科学会総会, Nov. 2016.
104.	Kouzou Yoshikawa, Mitsuo Shimada and Daichi Ishikawa : LTGにおけるOrVil法の有用性と視野展開の工夫, JDDW2016, Nov. 2016.
105.	Masato Yoshikawa, Yuji Morine, Tetsuya Ikemoto, Atsushi Takata, Toshiaki Yoshimoto, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Mitsuo Shimada : 当科における切除不能・再発進行膵癌に対する治療成績, 第54回日本癌治療学会学術集会, Oct. 2016.
106.	Daichi Ishikawa, 川下陽一郎, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : FBXW7発現は転移性肝癌における切除後再発予測因子となる, 第54回日本癌治療学会学術集会, Oct. 2016.
107.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : 末梢血Tr1細胞とFoxp3調節性T細胞は担癌状態におけるバイオメーカーとして有用である, 第54回日本癌治療学会学術集会, Oct. 2016.
108.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa and Masato Yoshikawa : 消化器癌におけるヒストンアセチル化の抗腫瘍効果, 第75回日本癌学会学術集会, Oct. 2016.
109.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Toshiaki Yoshimoto : Tr1とFoxp3陽性調節性T細胞は担癌患者の腫瘍免疫に関する検討, 第75回日本癌学会学術集会, Oct. 2016.
110.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Masato Yoshikawa and Daichi Ishikawa : 胃癌根治切除症例におけるPD1発現の意義, 第75回日本癌学会学術集会, Oct. 2016.
111.	Toshiaki Yoshimoto, Yu Saitou, Atsushi Takata, Masato Yoshikawa, Daichi Ishikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 脳死肝移植を推進するための学生に対するドナーアクションの必要性について, 第52回日本移植学会総会, Sep. 2016.
112.	Yu Saitou, Satoru Imura, Masato Yoshikawa, Daichi Ishikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 徳島におけるABO不適合生体肝移植の成績, 第52回日本移植学会総会, Sep. 2016.
113.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 術前診断が困難であった肝偽リンパ腫の1例, 第65回日本消化器画像診断研究会, Sep. 2016.
114.	Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 若手医師による術前術中3D simulation画像を用いた腹腔鏡下手術の定型化, 第11回肝癌治療シミュレーション研究会, Sep. 2016.
115.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Atsushi Takata and Toshiaki Yoshimoto : 肝細胞癌術後再発予後不良因子としてのCEAの意義, 第27回日本消化器癌発生学会総会, Sep. 2016.
116.	Daichi Ishikawa, Hiroki Teraoku, Atsushi Takata, Masato Yoshikawa, Chie Takasu, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 転移性肝癌における腫瘍悪性度制御因子としてのTHBS-1の役割, 第27回日本消化器癌発生学会総会, Sep. 2016.
117.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Hiroki Teraoku and Masato Yoshikawa : 肝内胆管癌の腫瘍悪性度評価と制御の可能性, 第27回日本消化器癌発生学会総会, Sep. 2016.
118.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa and Toshiaki Yoshimoto : 胆道癌術後肝内再発に対する肝切除導入効果の検証, 第91回中国四国外科学会総会/第21回中国四国内視鏡外科研究会, Sep. 2016.
119.	Chie Takasu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, 市井啓仁 and Mitsuo Shimada : 転写因子制御による肝虚血再灌流障害の新たな治療法の開発., 第253回徳島医学会学術集会, Jul. 2016.
120.	Yuji Morine, Mitsuo Shimada, Hiroki Ishibashi, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa and Masato Yoshikawa : 全国集計からみた膵・胆管合流異常症の臨床摘特徴と術式選択の現状., 第71回日本消化器外科学会総会, Jul. 2016.
121.	Masato Yoshikawa, Yu Saitou, Satoru Imura, Toshiaki Yoshimoto, Atsushi Takata, Daichi Ishikawa, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : ABO不適合生体肝移植後にCMV感染治療に難渋した一例., 第34回日本肝移植研究会, Jul. 2016.
122.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : NO阻害と転写活性制御からの虚血再灌流障害., 第34回日本肝移植研究会, Jul. 2016.
123.	Satoru Imura, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Intermediate stageの肝癌に対する肝切除は有効か?, 第52回日本肝癌研究会, Jul. 2016.
124.	Jun Higashijima, Daichi Ishikawa, Chie Takasu, Hideya Kashihara, Masaaki Nishi, Kouzou Yoshikawa and Mitsuo Shimada : Stage2,3直腸癌に対する腹腔鏡下手術の妥当性についての検討., 第85回大腸癌研究会, Jul. 2016.
125.	Toshiaki Yoshimoto, Kouzou Yoshikawa, 松本規子, Atsushi Takata, Yu Saitou, Masato Yoshikawa, Tetsuya Ikemoto, Satoru Imura, Yuji Morine, Daichi Ishikawa, Shuichi Iwahashi and Mitsuo Shimada : 青色LED光のヒト癌細胞株に対する効果., 第105回日本消化器病学会四国支部例会, Jun. 2016.
126.	Masato Yoshikawa, Yuji Morine, Tetsuya Ikemoto, Atsushi Takata, Toshiaki Yoshimoto, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Mitsuo Shimada : 切除不能・再発進行膵癌に対する治療成績., 第105回日本消化器病学会四国支部例会, Jun. 2016.
127.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yusuke Arakawa, Shuichi Iwahashi, Daichi Ishikawa, Masato Yoshikawa, Hiroki Teraoku and Toshiaki Yoshimoto : HCCに対して初回RFA治療早期にリンパ節再発をきたし外科的切除を施行した症例., 第41回日本外科系連合学会学術集会, Jun. 2016.
128.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu and Daichi Ishikawa : 腹腔鏡下胃全摘の再建におけるトラブルシューティング-Overlap法とOrVil法を経験して-., 第41回日本外科系連合学会学術集会, Jun. 2016.
129.	Toshiaki Yoshimoto, C Enkbold, Atsushi Takata, Masato Yoshikawa, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 肝内胆管癌における細胞周期調節因子Fbxw7発現低下の臨床病理学的意義., 第14回日本肝がん分子標的治療研究会, Jun. 2016.
130.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : RFA後肝細胞癌再発例はEMT誘導を介し腫瘍悪性度が増強する., 第14回日本肝がん分子標的治療研究会, Jun. 2016.
131.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Masato Yoshikawa : Tr1細胞とFoxp3調節性T細胞による膵嚢胞性疾患に関する正確な免疫学的指標探索に関する研究., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
132.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa and Jun Higashijima : 大腸癌多発肝転移に対する長期生存を目指した治療戦略., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
133.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku and Masato Yoshikawa : 肝内胆管癌に対する至適術式と集学的治療., 第116回日本外科学会定期学術集会, Apr. 2016.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

腫瘍関連線維芽細胞の脂質代謝に着目した腫瘍免疫制御のメカニズムの解明 (Project/Area Number: 24K23490 )
The impact of microRNA-449a on the cancer malignancy such as cancer stemness, epithelial-mesenchymal transition, and glycolysis. (Project/Area Number: 18K16257 )
The moleculer mechanisms of epithelial to mesenchymeal transition of primary gastrointestinal tumor from the point of view of endodermal embryology (Project/Area Number: 16H07015 )
Search by Researcher Number (70633882)

Assistant Professor : Ishikawa, Daichi

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)